Online Dispensary Area 52 Now Ships Legal Weed Nationwide
LAS VEGAS, NV / ACCESS Newswire / May 14, 2025 / Area 52 becomes the first and only online dispensary to ship premium cannabis legally to all 50 states. This breakthrough service follows their strict compliance with the 2018 Farm Bill, making quality weed available to everyone, regardless of local laws.
'We're the only company offering this nationwide shipping service for premium cannabis products,' said Area 52's founder. 'While others can't or won't ship across state lines, we've found the legal path forward.'
(click photo to visit Area 52)
Area 52's federally compliant products include:
Unlike competitors, all Area 52 products ship legally nationwide by containing less than 0.3% Delta-9 THC while delivering powerful effects.
'No other company can legally ship weed to all 50 states like we can,' the founder emphasized. 'This is a game-changer for people without local dispensary access.'
Every product includes a 60-day money-back guarantee and orders over $110 ship free.
Want legal weed delivered to your door? Area 52 is the only online dispensary that can ship to your state. Visit area52.com today, or click the photo below to browse all
CONTACT:
Ava Smith
[email protected]
SOURCE: area52ava
press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
5 hours ago
- Indianapolis Star
Abby Connect Launches Abby AI Receptionist, Built on 20 Years of Human Receptionist Expertise
A Smarter Way to Answer Every Call. Powered by AI, Backed by Human Expertise. LAS VEGAS, NV / ACCESS Newswire Abby Connect, a recognized leader in premium receptionist services, is proud to announce the launch of Abby AI Receptionist: a groundbreaking, 24/7 AI answering service powered by two decades of human receptionist experience. Abby AI Receptionist helps businesses reliably capture more leads, delight customers, and reduce operational costs without sacrificing the personal touch. Unlike standard chatbots or purely tech-driven AI assistants, Abby AI Receptionist is uniquely trained from millions of actual human receptionist interactions. Fluent in English and Spanish, it provides businesses with a smarter, scalable solution to the estimated $75 billion in annual losses from missed calls and poor first impressions. 'Small businesses don't need another generic AI bot-they need an intelligent receptionist solution trained from real-world conversations,' said Nathan Strum, CEO of Abby Connect. 'Abby AI offers exactly that: authentic conversations, real-time responsiveness, and our exclusive Human Backup On-Demand to seamlessly escalate calls whenever needed. It's the first AI built specifically by and for service professionals.' More Than a Virtual Assistant: An AI Trained by Humans Designed for busy professionals in law, real estate, franchise operations, trades, consulting, and other service-based businesses, Abby AI Receptionist delivers: 24/7 Call Answering: Capture leads and client calls around-the-clock in English and Spanish. Advanced Lead Capture: Intelligent new-client intake and qualification. Human Backup On-Demand: Abby Connect's unique guarantee-complex or sensitive calls seamlessly transfer to live U.S.-based receptionists. Smart Routing & Integration: Calls intelligently directed based on urgency or department, integrated seamlessly into CRMs, calendars, and business apps. Customized FAQs & Scripts: Tailored specifically for each business, improving call outcomes. 'Our clients need reliable after-hours coverage and AI that actually sounds human, without babysitting technology,' said Lisa Snyder, VP of Sales and Marketing. 'Abby AI delivers exceptional caller experiences, helping our clients sleep easier knowing they'll never miss another important call.' Flexible Pricing and Risk-Free Trial Businesses of any size can get started immediately with Abby AI's freemium plan (limited monthly minutes included), and paid plans offer more comprehensive solutions at competitive rates-no setup fees required. To celebrate the launch, Abby Connect is offering a risk-free 14-day trial of Abby AI's Starter, Essential, and Growth packages. Experience Abby AI Receptionist today at About Abby Connect Founded in 2005, Abby Connect is a premier provider of live receptionist services and innovative AI-driven communication solutions. Abby helps businesses grow by making every conversation count, whether handled by a real person, Abby's proprietary AI, or a seamless blend of both. Media Contact: press@ | (877) 303-5757 SOURCE: Abby Connect
Associated Press
6 hours ago
- Associated Press
NBJ Summit 2025 Brings Industry Visionaries Together to Shape Nutrition's Future
RANCHO PALOS VERDES, CA / ACCESS Newswire / June 11, 2025 / The nutrition and dietary supplements industry's premier gathering, NBJ Summit 2025, will convene top executives and thought leaders at the Terranea Resort in Rancho Palos Verdes, Calif. from July 28-31, 2025. With the central theme of 'Nutrition Industry Transformation,' this year's summit addresses the seismic shifts reshaping the nearly $70 billion dollar industry landscape. This year's event comes at a critical time, promising to mobilize leaders around topics presenting challenges and opportunities for consumers and the industry. The NBJ Summit, hosted by New Hope Network, offers an unparalleled opportunity for industry leaders to engage in four days of intensive education, strategic networking and forward-thinking discussions about the future of nutrition and dietary supplements. The State of the Industry presentation featuring Nutrition Business Journal (NBJ) industry data will set the stage for the week. 'In an era of exponential change, this year's agenda directly confronts the forces reshaping our industry and provides executives with actionable strategies to thrive amid disruption,' says Jessica Rubino, VP of Content and Summits, who serves as NBJ Summit Co Chair, along with Bill Giebler, Nutrition Business Journal Content & Insights Director, and Tom Aarts, NBJ Summit Founder 'We're bringing together the most innovative leaders to navigate this new landscape where healthcare and supplement industry convergence, digital transformation, regulatory shifts and personalized nutrition are fundamentally reshaping our industry.' The 2025 agenda addresses four critical transformation areas: A disruptive perspective on healthcare economics will be delivered by Calley Means, Co-Founder of Truemed, featuring compelling data demonstrating nutrition's critical role in addressing systemic health challenges. Complementing this vision, Dr. Lise Alschuler will reveal clinical pathways reshaping patient care, while James LaValle demonstrates how scientific insights create market advantages for forward-thinking companies. Dr. William Davis rounds out this powerful segment by sharing an influential vision for the nutrition-centered health transformation changing consumer expectations. Business transformation renders yesterday's business models obsolete, and the Summit brings together leading experts in technology and innovation. AI specialists Mitch Mitchum, HIVE Interactive; Afif Ghannoum, CPG Radar; and Akash Shah, IngredientAI will reveal strategic applications of artificial intelligence that are driving growth across the nutrition value chain. Plus, innovation catalyst Diana Kander delivers a highly anticipated keynote on curiosity-driven innovation, offering attendees a rare opportunity to learn from one of today's most sought-after business advisors whose insights have transformed companies across multiple industries. The regulatory landscape continues to evolve at an unprecedented pace, creating both challenges and opportunities for nutrition businesses. Industry advocates Douglas 'Duffy' MacKay, ND; Miriam Guggenheim of Covington & Burling LLP; and Steve Mister, Esq., President & CEO of the Council for Responsible Nutrition, will provide essential insights on compliance challenges and policy shifts reshaping the competitive landscape. MacKay and Mister's collective expertise offers attendees a comprehensive understanding of how to navigate complex regulatory environments while maintaining competitive advantage. As the future of nutrition and retail are increasingly individualized, the Summit aims to showcase the pioneers leading this revolution. Biohacking phenomenon Ben Greenfield will share cutting-edge optimization techniques that are redefining consumer expectations around personalized nutrition. Renowned longevity researcher Brian Kennedy will reveal breakthroughs in cognitive enhancement, creating entirely new market categories. Retail experts from Amazon, TikTok and more will also share invaluable insights on emerging trends shaping the future of supplement retail in a personalized and omnichannel world, offering attendees practical strategies for adapting to rapidly evolving consumer behaviors and expectations. The Summit culminates in an Executive Wellness Experience featuring a meticulously crafted Wellness Lunch, intimate networking with industry leaders and hands-on experiences with emerging biohacking modalities, nourishing wellness treatments and functional libations. The NBJ Summit welcomes top nutrition industry CEOs and executives to this exclusive in-person event. For registration information and the complete agenda, visit NBJ Summit offers virtual registration to all who are interested. Virtual participants will have access to all education sessions, networking opportunities and will be able to connect with both in-person and virtual attendees on the virtual event platform. For more information, please visit About Nutrition Business Journal Nutrition Business Journal guides decision makers in the nutrition, health, and wellness space in developing their strategy, understanding trends, realizing opportunity, and analyzing potential risks. NBJ's market research reports provide business intelligence and thought leadership to all levels of the nutrition industry. Each report is exhaustively researched by our staff of industry experts and presents an analysis of markets, trends, competition, and strategy in the U.S. and global nutrition industry. Learn more at About Informa Markets Informa Markets, a subsidiary of Informa plc (LON:INF), creates platforms for industries and specialist markets to trade, innovate and grow. With a global reach and diverse portfolio of verticals, including Pharmaceuticals, Food, Medical Technology and Infrastructure, Informa Markets connects buyers and sellers worldwide through face-to-face exhibitions, targeted digital services and actionable data solutions. For more information, visit Media Contact [email protected] SOURCE: New Hope Network press release
Indianapolis Star
7 hours ago
- Indianapolis Star
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer from CID to treatment of general, non-infectious diarrhea in dogs Jaguar in discussions with potential partners to license and fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs SAN FRANCISCO, CA / ACCESS Newswire / June 11, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, today announced that the first study site has been established for Jaguar's field study of Canalevia-CA1, Jaguar's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Jaguar has two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) in dogs and to expand the indication of crofelemer from CID in dogs to treatment of general, non-infectious diarrhea in dogs. The company is in discussions with potential partners to fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally. 'We've been pleased with the marketplace reception of crofelemer for treatment of CID in dogs, and believe there is clearly an unmet medical need for a product for the much larger market of treatment of general, non-infectious diarrhea in dogs,' said Lisa Conte, Jaguar's Founder and CEO. 'We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs, and we look forward to identifying a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in the U.S and/or globally. Forging a partnership for this purpose is a key focus of our business development efforts in 2025 and has been designated as a key potential catalyst for the company this year.' 'Jaguar's canine-focused business development efforts align with our ongoing business development efforts on the 'human' side of the company for crofelemer – the catalysts for which are the pathways discussed with the FDA to bring crofelemer to metastatic breast cancer patients, a population we feel meets the requirements for orphan drug status; and the prompt establishment of an expanded access program for crofelemer for the ongoing important unmet medical need of cancer therapy-related diarrhea in breast cancer patients; and the initial proof-of-concept results from the ongoing investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer in Abu Dhabi in pediatric patients with intestinal failure due to the orphan diseases microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). As recently announced, the initial proof-of-concept results of this IIT show crofelemer reduced the required total parenteral nutrition (TPN) and/or supplementary intravenous fluids, collectively referred to as parenteral support, in patients with intestinal failure due to MVID and short bowel syndrome by up to 27% and 12.5% respectively.' The objective of the prospective, randomized, open-label field study in dogs undergoing chemotherapy treatment across the U.S. is to collect real-world data to demonstrate real-world evidence of the clinical effectiveness for Canalevia-CA1 for the treatment of CID in dogs to support potential full FDA approval of the drug for this indication. Dogs enrolled in this study will be randomly assigned to receive a prescription of Canalevia-CA1 as a treatment for CID or be randomly selected to the control group. As announced, Jaguar established a new Investigational New Animal Drug (INAD) file with the FDA's Center for Veterinary Medicine for crofelemer to treat general, non-infectious diarrhea in dogs. Diarrhea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drug to treat canine general, non-infectious diarrhea. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (45.5%) of U.S. households owning a dog in 2024. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of control in urban settings where owners don't have easy access to outdoor facilities is a significant problem for families with dogs. Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary distributors in the U.S., including Chewy. About Conditional Approval and Full Approval Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA's conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the 'substantial evidence' standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving 'substantial evidence of effectiveness' for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug. About Chemotherapy-induced Diarrhea (CID) in Dogs According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer. 1 According to the National Cancer Institute, which is part of the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S. Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment, 2 and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients' chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID. Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs. About Canalevia ® -CA1 Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a 'small number' threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use. About Crofelemer Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities. Important Safety Information About Canalevia ® -CA1 For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute 'forward-looking statements.' These include statements regarding Jaguar's expectation that it will identify a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S and/or globally, Jaguar's expectation that the U.S. population of metastatic breast cancer patients meets the requirements for orphan drug status, Jaguar's expectation that it will promptly establish an expanded access program for crofelemer for cancer therapy-related diarrhea in breast cancer patients, and Jaguar's expectation that the field study of Canalevia-CA1 for the treatment of CID in dogs will support potential full FDA approval of the drug for this indication. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 1 'Cancer in Pets.' American Veterinary Medical Association, 2021, 2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398 Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc.
